Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform

Eli Lilly's obesity drug, Mounjaro, has shown promising results, leading to speculation about the company's potential in the obesity market. However, the stock's future depends on factors like pipeline progress, manufacturing, pricing, and earnings trajectory.